AIM: A recent report on intravenous (i.v.) paracetamol pharmacokinetics (PK) showed a higher total clearance in women at delivery compared with non-pregnant women. To describe the paracetamol metabolic and elimination routes involved in this increase in clearance, we performed a population PK analysis in women at delivery and post-partum in which the different pathways were considered. METHODS: Population PK parameters using non-linear mixed effect modelling were estimated in a two-period PK study in women to whom i.v. paracetamol (2 g loading dose followed by 1 g every 6 h up to 24 h) was administered immediately following Caesarean delivery and in a subgroup of the same women to whom single 2 g i.v.loading dose was administered 10-15 weeks post-partum. RESULTS: Population PK analysis was performed based on 255 plasma and 71 urine samples collected in 39 women at delivery and in eight of these 39 women 12 weeks post-partum. Total clearance was higher in women at delivery compared with 12th post-partum week (21.1 vs. 11.7 l h⁻¹) due to higher clearances to paracetamol glucuronide (11.6 vs. 4.76 l h⁻¹), to oxidative metabolites (4.95 vs. 2.77 l h⁻¹) and of unchanged paracetamol (1.15 vs. 0.75 l h⁻¹). In contrast, there was no difference in clearance to paracetamol sulphate. CONCLUSION: The increased total paracetamol clearance at delivery is caused by a disproportional increase in glucuronidation clearance and a proportional increase in clearance of unchanged paracetamol and in oxidation clearance, of which the latter may potentially limit further dose increase in this patient group.
AIM: A recent report on intravenous (i.v.) paracetamol pharmacokinetics (PK) showed a higher total clearance in women at delivery compared with non-pregnant women. To describe the paracetamol metabolic and elimination routes involved in this increase in clearance, we performed a population PK analysis in women at delivery and post-partum in which the different pathways were considered. METHODS: Population PK parameters using non-linear mixed effect modelling were estimated in a two-period PK study in women to whom i.v. paracetamol (2 g loading dose followed by 1 g every 6 h up to 24 h) was administered immediately following Caesarean delivery and in a subgroup of the same women to whom single 2 g i.v.loading dose was administered 10-15 weeks post-partum. RESULTS: Population PK analysis was performed based on 255 plasma and 71 urine samples collected in 39 women at delivery and in eight of these 39 women 12 weeks post-partum. Total clearance was higher in women at delivery compared with 12th post-partum week (21.1 vs. 11.7 l h⁻¹) due to higher clearances to paracetamol glucuronide (11.6 vs. 4.76 l h⁻¹), to oxidative metabolites (4.95 vs. 2.77 l h⁻¹) and of unchanged paracetamol (1.15 vs. 0.75 l h⁻¹). In contrast, there was no difference in clearance to paracetamol sulphate. CONCLUSION: The increased total paracetamol clearance at delivery is caused by a disproportional increase in glucuronidation clearance and a proportional increase in clearance of unchanged paracetamol and in oxidation clearance, of which the latter may potentially limit further dose increase in this patient group.
Authors: A Kulo; M van de Velde; J de Hoon; R Verbesselt; R Devlieger; J Deprest; K Allegaert Journal: Int J Obstet Anesth Date: 2012-02-15 Impact factor: 2.603
Authors: K W Bock; A Forster; H Gschaidmeier; M Brück; P Münzel; W Schareck; S Fournel-Gigleux; B Burchell Journal: Biochem Pharmacol Date: 1993-05-05 Impact factor: 5.858
Authors: Karel Allegaert; Brian J Anderson; Gunnar Naulaers; Jan de Hoon; Rene Verbesselt; Anne Debeer; Hugo Devlieger; Dick Tibboel Journal: Eur J Clin Pharmacol Date: 2004-04-08 Impact factor: 2.953
Authors: T W Hahn; T Mogensen; C Lund; L S Jacobsen; N-C Hjortsoe; S N Rasmussen; M Rasmussen Journal: Acta Anaesthesiol Scand Date: 2003-02 Impact factor: 2.105
Authors: Aida Kulo; Sarah Hendrickx; Jan de Hoon; Nedzad Mulabegovic; Kristel van Calsteren; Rene Verbesselt; Karel Allegaert Journal: Eur J Drug Metab Pharmacokinet Date: 2012-11-21 Impact factor: 2.441
Authors: Ira Kantrowitz-Gordon; Karen Hays; Olumide Kayode; Aditya R Kumar; Henry G Kaplan; Joel M Reid; Stephanie L Safgren; Matthew M Ames; Thomas R Easterling; Mary F Hebert Journal: Cancer Chemother Pharmacol Date: 2018-01-05 Impact factor: 3.333
Authors: Aida Kulo; Anne Smits; Sanita Maleškić; Marc Van de Velde; Kristel Van Calsteren; Jan De Hoon; Rene Verbesselt; Jan Deprest; Karel Allegaert Journal: Bosn J Basic Med Sci Date: 2017-02-21 Impact factor: 3.363
Authors: Sarah F Cook; Chris Stockmann; Samira Samiee-Zafarghandy; Amber D King; Nina Deutsch; Elaine F Williams; Diana G Wilkins; Catherine M T Sherwin; John N van den Anker Journal: Clin Pharmacokinet Date: 2016-11 Impact factor: 6.447
Authors: Amit A Somani; Kirstin Thelen; Songmao Zheng; Mirjam N Trame; Katrin Coboeken; Michaela Meyer; Katrin Schnizler; Ibrahim Ince; Stefan Willmann; Stephan Schmidt Journal: Br J Clin Pharmacol Date: 2015-10-30 Impact factor: 4.335
Authors: Elke H J Krekels; Saskia van Ham; Karel Allegaert; Jan de Hoon; Dick Tibboel; Meindert Danhof; Catherijne A J Knibbe Journal: Eur J Clin Pharmacol Date: 2015-07-03 Impact factor: 2.953
Authors: Jin Kyung Lee; Hye Jin Chung; Liam Fischer; James Fischer; Frank J Gonzalez; Hyunyoung Jeong Journal: Drug Metab Dispos Date: 2014-01-09 Impact factor: 3.922